Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FANCA Q1307Sfs*6 |
Therapy | Cisplatin + Olaparib |
Indication/Tumor Type | hepatocellular carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FANCA Q1307Sfs*6 | hepatocellular carcinoma | predicted - sensitive | Cisplatin + Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Platinol (cisplatin) combination treatment resulted in decreased tumor marker level within 1 month and disease stabilization with a progression-free survival of 12 months in a patient with hepatocellular carcinoma harboring FANCA Q1307Sfs*6 (PMID: 36181052). | 36181052 |
PubMed Id | Reference Title | Details |
---|---|---|
(36181052) | Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. | Full reference... |